Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've made money in this stock and it looks good, but I watch my charts. IMO news or no news it needs to touch the 10 dma before it moves up again. Nothing is 100%, I could be wrong, but I'll take my chances on my being correct. GLTA
AVL, MCP, REE all up big today.
Did you mean disguised?
MMs playing games.
180,000 shares @ .05
At what price do you plan on loading your boat?
It was an email reply I received from Hank Law.
The Plan of Reorganization you can find linked on this page says QSGI intends to merge with KruseCom. The creditors voted 99% positive to accept that plan. The judge held a confirmation hearing today to review the results of that vote.
If you have any doubts, PACER and SEC filings will document the results within a day or two.
Thanks,
Hank Laws
KruseCom
561-602-2098
--------------------------------------------------------------------------------
From: [mailto:kell50us@yahoo.com]
Sent: Monday, March 21, 2011 4:49 PM
To: Hank Laws
Subject: RE: Customer Service Request
Is QSGI merging with krusecom?
www.qsgiinc.com
The Plan of Reorganization you can find linked on this page says QSGI intends to merge with KruseCom. The creditors voted 99% positive to accept that plan. The judge held a confirmation hearing today to review the results of that vote.
If you have any doubts, PACER and SEC filings will document the results within a day or two.
Thanks,
Hank Laws
KruseCom
561-602-2098
What pps are you averaged in at?
I'm with you on that.
I agree. I'm going to keep holding CSKH. Chartwise it has very good potential. People are definitely accumulating at these levels.
It may be and I hope so, but I always trust my charts. CSKH has a lot of resistance points on the way up. I am long CSKH.
Usually when the funds are in your account even if they are not settled you can still buy a stock, but you have to hold it for a minimum of 3 days before you can sell it.
Resistance @ .064.
ARIA..$6.28....nice chart.
DEPO..$8.51 trading down after hours.
????
Depomed Licenses Acuform® Technology and Glumetza® Data to Boehringer Ingelheim
Press Release Source: Depomed Inc On Tuesday March 15, 2011, 7:00 am EDT
http://finance.yahoo.com/news/Depomed-Licenses-Acuform-thomsonreuters-2668851130.html?x=0&.v=1
ANIK..$9.75, hod $10.11
Anika Therapeutics Reports 39% Total Revenue Growth in Fourth
Quarter 2010
http://finance.yahoo.com/news/Anika-Therapeutics-Reports-39-bw-4282516001.html?x=0&.v=1
BLTI..$4.53 hod $4.60, SPPI..$7.18 hod $7.38, AMRN..$7.23 hod $7.26. These are moving well on a very RED day.
Spectrum Pharmaceuticals Reports Profitable Fourth Quarter and Record Revenue Growth for 2010
Related Quotes
Symbol Price Change
SPPI 6.90 0.00
Press Release Source: Spectrum Pharmaceuticals On Thursday March 10, 2011, 7:00 am EST
IRVINE, Calif.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS:SPPI - News), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today reported financial results for the three and 12-months ended December 31, 2010.
“We are proud of our many accomplishments in 2010, especially the record revenue growth of both of our proprietary, marketed, anti-cancer drugs, FUSILEV® and ZEVALIN®, and the licensing of belinostat, a late-stage, potentially best-in-class HDAC inhibitor for potentially multiple indications,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals, Inc. “We remain committed to lymphoma. The cash generated by the record product sales provides us greater opportunity to help cancer patients by initiating additional studies for ZEVALIN, such as in Diffuse Large B-Cell Lymphoma, and for our other pipeline drugs.”
Fourth Quarter Results Ended December 31, 2010 (All #s are approximates)
Consolidated revenue of $34 million was comprised of product sales of $31 million ($8 million from ZEVALIN, $23 million from FUSILEV) and $3 million from licensing fees. This represents a more than three-fold increase over the $9 million in consolidated revenue in the fourth quarter of 2009, which was comprised of $5 million from product sales and the balance from licensing and milestone fees. The Company recorded net income of $4 million, or $0.09 per basic and $0.08 per diluted share, compared to net income of $10 million, which includes income of $20 million from the change in the fair value of common stock warrant liability, or $0.21 per basic and $0.20 per diluted share, in the fourth quarter of 2009. Total research and development expenses were $7 million, as compared to $4 million in the same period of 2009, primarily due to in-licensing of compounds and continued investment in clinical trials. Selling, general and administrative expenses were $13 million compared to $11 million in the same period in 2009, an increase primarily attributable to sales and marketing expenses, including payroll costs and non cash stock compensation costs incurred with the sales of ZEVALIN and FUSILEV.
12-Month Results Ended December 31, 2010 (All #s are approximates)
Consolidated revenue of $74 million was comprised of product sales of $61 million ($29 million from ZEVALIN, $32 million from FUSILEV) and $13 million from licensing fees. This represents a nearly two-fold increase from $38 million in consolidated revenue recorded in 2009, which was comprised of $28 million from product sales ($16 million from ZEVALIN, $12 million from FUSILEV) and $10 million from milestone and licensing fees. The Company recorded a net loss attributable to stockholders’ of $49 million, or ($0.99) per basic and diluted share, compared to a net loss attributable to stockholders’ of $19 million, or ($0.48) per basic and diluted share, in the same period of 2009. Total research and development expenses were $57 million, as compared to $21 million in the same period of 2009, primarily due to the $30 million upfront payment for the licensing of belinostat, and a one-time charge of $3 million, representing the fair value of 751,956 shares of our common stock issued as consideration for the acquisition and licensing of compounds. Selling, general and administrative expenses were $49 million compared to $34 million in the same period in 2009 an increase primarily due to the $14 million increase attributable to sales and marketing expenses, including payroll costs, incurred with the increase in sales of ZEVALIN and FUSILEV.
Cash, cash equivalents and investments as of December 31, 2010 aggregated $104 million, as compared to $125 million as of December 31, 2009, a net decrease of $21 million including the $30 million used for the in-licensing of belinostat.
There are approximately 51 million shares of common stock issued and outstanding at December 31, 2010. Approximately 7 million warrants expired unexercised in 2010.
2011/2012 Corporate Events and Potential Valuation Catalysts
FUSILEV®
•FDA PDUFA Action date in metastatic colorectal cancer by April 29, 2011.
ZEVALIN®
•Anticipate FDA decision on bioscan removal before the end of 2011;
•Initiation of a Diffuse Large B-Cell Lymphoma trial in 2011.
Belinostat
•Complete enrollment in registrational study and file rolling NDA for Peripheral T-Cell Lymphoma in 2011/2012.
Apaziquone
•Anticipate filing NDA for bladder cancer in 2012.
Conference Call
Thursday, March 10, 2011 @ 1:30 p.m. Eastern/10:30 a.m. Pacific
Domestic: (877) 837 - 3910
International: (973) 796 - 5077
Webcast and replays: www.sppirx.com
Audio replays will be available through April 1, 2011
Domestic: (800) 642-1687, passcode 43097899
International: (706) 645-9291, passcode 43097899
http://finance.yahoo.com/news/Spectrum-Pharmaceuticals-bw-1450917997.html?x=0&.v=1
AMRN..it's dropping on lower volume. Patience..
AMRN..$7.03. Next support @ 100 dma $6.45. If it makes it there I will buy more shares.
Glad to hear it went well, now relax and make some money:)
Yes, but the facts in the report have all been reported before. This is a synopsis of it basically.
NEOP..nice 50 page report about Neoprobe by LIFESCI ADVISORS.
http://www.lifesciadvisors.com/clientinfo/neoprobe/NEOP_LSA_Initiation_3-8-11.pdf
IMUC.OB-ImmunoCellular..$2.35
From Seeking Alpha
Shares of ImmunoCellular Therapeutics, Ltd. (IMUC.OB) have pulled back during the last two sessions, thereby testing some newly formed support at the $2.22 level. We look for shares of the company to continue rising in anticipation of an uplisting to the AMEX. Sources close to the NYSE Amex told us that the company has been looking into uplisting and that an official announcement should follow soon.
Last week, ImmunoCellular raised approximately $8.1 million primarily from U.S. based institutional investors and the stock reacted very bullishly to the news, dipping only slightly before resuming their climb.
A move to the Amex by ImmunoCellular would undoubtedly let institutions and other funds who can't otherwise buy the stock to begin accumulating it, therefore causing prices to rise, just as they did for Neoprobe Corporation (AMEX: NEOP). ImmunoCellular has ICT107 - a new generation dendritic cell-based therapeutic vaccine in human trials. Early last month, IMUC announced that the first patient had been enrolled in its Phase II trial of ICT-107 at the New Jersey Neuroscience Institute at JFK Medical Center. As our readers know, ICT107 is being developed in the form of intradermal injection as a therapeutic vaccine for glioblastoma multiforme.
We are told that management teams from at least two other immunotherapy focused small-cap firms are watching this move by IMUC with a close eye. Should ImmunoCellular prove to be successful in raising their market valuation, those companies will look to make uplisting moves of their own, especially since a couple of them have pending good news developments that we keep hearing about and may validate their technologies. Stay tuned for more news on that in the days ahead.
Repligen bipolar depression drug fails in study
On Monday March 7, 2011, 11:00 am EST
WALTHAM, Mass. (AP) -- Repligen Corp. said Monday that a mid-stage clinical trial showed one of its drug candidates was no more effective than a placebo in treating bipolar depression.
The results sent Repligen shares tumbling more than 25 percent in morning trading.
The company said the drug, RG2417, was not significantly better than a placebo. The study involved 175 patients who took the drug or the placebo for eight weeks, measuring their symptoms on a 10-item clinical diagnostic survey. Repligen said it will review data from the study and decide if it will continue developing the drug, which is also called uridine.
The company said patients who were enrolled in the study through academic medical centers did significantly better, but in patients who were enrolled through commercial clinical trial sites, there was no difference between RG2417 and placebo. There were 50 patients enrolled through academic sites and 125 through commercial sites. Repligen said it planned to look into those differences.
Repligen is also testing a pancreatic imaging agent and a treatment for Friedreich's ataxia, a genetic disorder that leads to degeneration of the nerves controlling muscle movements in the arms and legs and the nerve tissue in the spinal cord.
Shares of Repligen dropped $1.26, or 25.7 percent, to $3.65 in morning trading. The stock has traded between $3 and $5.36 in the last year.
DEPO..$9.04 new HOD
FCSC-$.92, DEPO;$8.92, AMRN-$7.60 all up on a down day, nice.
I saw that, BPAX is trading down this a.m.
Understood. I was just referring to buy the rumor sell the news. Mostly just rambling out loud.
CLDX..sell the news?
Nice chart on USSIF.
BPAX..7:55AM BioSante's pancreas cancer vaccine shows survival increase in newly published study (BPAX) 2.03 : Co announces publication of results from a Phase II clinical study that show BioSante's Pancreas Cancer Vaccine increased the median survival of resected pancreatic cancer patients from 15 to 20 months, as reported in published data, to 24.8 months, an increase of more than 25 percent. In addition, the vaccine demonstrated a 35 percent increase in one year survival, from 63 percent to 85 percent. A new multicenter clinical study is planned to begin this year.
Press Release Source: BioSante Pharmaceuticals, Inc. On Thursday March 3, 2011, 7:55 am
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)-- BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX - News) today announced publication of results from a Phase II clinical study that show BioSante’s Pancreas Cancer Vaccine increased the median survival of resected pancreatic cancer patients from 15 to 20 months, as reported in published data, to 24.8 months, an increase of more than 25 percent. In addition, the vaccine demonstrated a 35 percent increase in one year survival, from 63 percent to 85 percent. A new multicenter clinical study is planned to begin this year.
In the study, titled, “A Lethally Irradiated Allogeneic GM-CSF-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation,” published in the February 2011 issue of Annals of Surgery, the primary endpoint was disease free survival and secondary endpoints were overall survival and toxicity, and the induction of mesothelin specific T cell responses. The median disease-free survival of patients was 17.3 months (95% CI, 14.6–22.8) with median survival of 24.8 months (95% CI, 21.2–31.6). The administration of immunotherapy was well tolerated. In addition, the postimmunotherapy induction of mesothelin-specific T cells in patients correlates with disease-free survival. The investigators concluded that “an immunotherapy approach integrated with chemoradiation is safe and effective for resected pancreas cancer.”
The 60 patient Phase II study was conducted by researchers at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland. The research was funded by the National Institutes of Health and other foundations. BioSante’s Pancreas Cancer Vaccine is made from allogeneic pancreatic cancer cells genetically altered to produce an immune system stimulator called GM-CSF, and irradiated to prevent cell growth. BioSante already has received Orphan Drug designation from the U.S. Food & Drug Administration for the Pancreas Cancer Vaccine
“We are very excited by the positive results of this study. This is encouraging news concerning potential treatment for a disease that can be so devastating for so many patients,” said Stephen M. Simes, BioSante’s president & CEO. “Besides pancreatic cancer, Johns Hopkins researchers also are investigating the use of BioSante’s cancer vaccines for the treatment of several different forms of cancer, including leukemia, breast cancer and multiple myeloma. We look forward to continuing our collaboration with this well-respected research institute as further studies are conducted.”
NVAX..$3.40 this morning.
AEZS..Aeterna Zentaris Receives $2.5 Million Milestone Payment From Cowen Healthcare Royalty Partners.
Press Release Source: AETERNA ZENTARIS INC. On Monday February 28, 2011, 7:50 am
All amounts are in U.S. dollars
QUEBEC CITY, Feb. 28 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:AEZS - News) (TSX:AEZ.to - News) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that it had received a net sales milestone of $2.5 million from Cowen Healthcare Royalty Partners, L.P. ("Cowen Royalty"). This milestone was payable pursuant to the previously announced sale to Cowen Royalty of Aeterna Zentaris' rights to royalties on future net sales of Cetrotide®, covered by the Company's license agreement with Merck Serono, and was contingent on 2010 net sales of Cetrotide® reaching a specified level.
Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris stated, "We are pleased to have reached this $2.5 million milestone which will be incremental to advance perifosine, AEZS-108 and other innovative oncology compounds from our extensive product pipeline."
http://finance.yahoo.com/news/Aeterna-Zentaris-Receives-25-prnews-2430589942.html?x=0&.v=1
Nobody is upset, I was just trying to find out where the report came from. No harm intended on my part.
AMRN, $7.50 is ok with me. Dry powder tomorrow, will pick up some more shares. Maybe there is a stock god. LOL
Per PLX website:Analysts
Firm Analyst
CANACCORD Genuity Ritu S. Baral
Capstone Investments Difei Yang
Hapoalim Securities Jon Lecroy
Noble Financial Capital Markets Raghuram Selvaraju
Oppenheimer Bret Holly
UBS Research Chris Schaefer
WBB Securities Daniel T. Mallin
Wells Fargo Brian Abrahams, M.D.
I don't see any MP Advisors. Do you have a link for this MP advisors report?
OSUR- Canaccord raises Orasure Technologies price target to $10 from $8.